美国新诊断急性髓系白血病初始化疗的使用情况
基于美国国家癌症数据库2003至2011年诊断的61775例成人急性髓系白血病患者,采用多变量逻辑回归分析初始化疗使用情况。15608例(25.3%)未接受化疗,年龄和合并症增加、治疗相关及中/高危AML与化疗使用可能性降低相关,非学术中心诊疗、非裔美国人种族、低收入、无保险或Medicare保险及女性也与较低化疗使用可能性相关。
要点
- 15608例(25.3%)成人AML患者未接受初始化疗。
- 年龄和合并症增加与接受化疗可能性降低相关。
- 非学术中心、非裔美国人、低收入、无保险或Medicare及女性与较低化疗使用可能性相关。
核心结论
- 研究结果提出基于社会经济和卫生系统因素的白血病诊疗差异的可能性。
- 更好地理解这些因素影响化疗使用的方式可能有助于增加化疗的使用。
研究设计与样本
- 纳入美国国家癌症数据库2003年至2011年诊断的61775例成人急性髓系白血病患者。
- 采用多变量逻辑回归模型确定接受化疗与多个因素之间的关联。
主要发现
- 15608例患者(25.3%)未接受化疗。
- 多变量分析中,接受化疗的可能性随年龄和合并症增加而下降。
- 治疗相关及中/高危AML患者接受化疗的可能性降低。
- 非学术中心诊疗、非裔美国人种族、低收入状态、无保险或Medicare保险状态及女性与接受化疗可能性降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of chemotherapy in patients with acute myeloid leukemia (AML) is associated with survival benefits and alleviation of symptoms related to AML. Prior studies have demonstrated a lower receipt of chemotherapy with increasing age and comorbidities. We hypothesized that socioeconomic and health system factors also determine the use of chemotherapy. We included 61 775 adults with AML diagnosed between 2003 and 2011 from the National Cancer Database, and performed a multivariable logistic regression model to determine the association between receipt of chemotherapy and several factors. A total of 15 608 patients (25.3%) did not receive chemotherapy. In a multivariable analysis, the likelihood of getting chemotherapy declined with increasing age and comorbidities and among patients with therapy-related and intermediate-/high-risk AML. Other factors associated with a lower likelihood of receiving chemotherapy included receipt of care in nonacademic centers, African American race, lower income status, uninsured or Medicare insurance status, and female sex. Compared with the previous studies, our study is novel because it provides data from a large, unselected cohort of patients diagnosed in the United States in recent years, and simultaneously examines the effect of various biological, socioeconomic, and health system factors. The results of our study raise a possibility of leukemia care disparity based on socioeconomic and health system factors. Better understanding of ways such factors may influence receipt of chemotherapy may allow an increase in the use of chemotherapy.
引用
- Bhatt VR, Shostrom V, Gundabolu K, et al. Utilization of initial chemotherapy for newly diagnosed acute myeloid leukemia in the United States. Blood Adv. 2018. PMID: 29880697. doi:10.1182/bloodadvances.2018019125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。